Han Sen Pharmaceutical granted Regeneron exclusive overseas license for investigational GLP-1/GIP dual receptor agonist HS-20094.

Hans Pharmaceuticals announced a licensing agreement with Regeneron Pharmaceuticals, Inc., granting Regeneron exclusive global rights to develop, manufacture, and commercialize HS-20094. Under the agreement, Hans Pharmaceuticals will receive an upfront payment of $80 million and is eligible to receive up to $1.93 billion in milestone payments based on product development, regulatory approval, and commercialization milestones, as well as a double-digit percentage of future potential product sales as royalty fees.